Use of intravitreal rituximab and methotrexate in vitreoretinal lymphoma

Eur J Ophthalmol. 2022 Jan;32(1):NP199-NP202. doi: 10.1177/1120672120960589. Epub 2020 Sep 28.

Abstract

A 64-year-old Caucasian woman was referred to our hospital after referring vision loss; she had been previously diagnosed with systemic diffuse large B-cell lymphoma. Retinal and optic nerve involvement were found in her right eye, and iris and vitreous involvement were found in her left eye. Vitreoretinal lymphomas (VRL) are rare in medical literature, hence there is a lack of standardised studies regarding therapeutic options in these patients. In our patient, we decided to add intravitreal injections of rituximab and methotrexate to systemic chemotherapy, and to perform pars plana vitrectomy.

Keywords: Diffuse large B-cell lymphoma; methotrexate; rituximab; vitreoretinal lymphoma.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Methotrexate
  • Middle Aged
  • Retinal Neoplasms* / drug therapy
  • Retrospective Studies
  • Rituximab
  • Vitreous Body

Substances

  • Rituximab
  • Methotrexate